Standard Corneal Collagen Crosslinking Versus Transepithelial Corneal Crosslinking by Iontophoresis of Riboflavin

NCT ID: NCT02456961

Last Updated: 2015-05-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

126 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The standard CXL technique involves removal of the epithelium to enable riboflavin to penetrate into stromal tissue, to avoid epithelial debridement and increasing the patient's comfort and safety transepithelial corneal crosslinking (CXL) was suggested. Iontophoresis of riboflavin is one of approach for riboflavin impregnation.

In this study, the investigators compared the results of standard corneal crosslinking (CXL) and transepithelial CXL via iontophoresis of riboflavin after 24 months follow up.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Keratoconus

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Collagen crosslinking (CXL) Standard corneal crosslinking (CXL) Transepithelial CXL Iontophoresis Riboflavin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard epithelium-off CXL

Removing the central 8-10mm of the epithelium and applying a riboflavin solution (0.1% riboflavin-5-phosphate and 20% dextran T-500) to the corneal surface 30 minutes before irradiation and at 5 minutes intervals during the course of a 30 minute exposure to 370 nm UVA with an irradiance of 3 mWcm-2 (UFalink, Russian Federation)

Group Type ACTIVE_COMPARATOR

epithelium-off

Intervention Type PROCEDURE

Corneal collagen crosslinking

Intervention Type PROCEDURE

Standard surface UVA irradiation (370 nm, 3 mW/cm2; UFalink, Russian Federation) was then applied at a 5-cm distance for 30 minutes. During UVA exposure, hypotonic riboflavin drops were continued every 2 minutes.

Dextralink

Intervention Type DRUG

Riboflavin 0,1% + Dextran T-500

UFalink

Intervention Type DEVICE

device for UVA irradiation - providing UVA light - 370 nm, 3 mW/cm2

Transepithelial CXL via iontophoresis of riboflavin

impregnation of the cornea with a riboflavin 0.1% hypotonic solution is performed by using an iontophoresis device (galvanizator; Potok-1, Russian Federation). The passive electrode (anode) was applied to the inferior part of the cervical vertebrae. The active electrode (cathode), a bath tube (glass or plastic - 10-12 ml) is applied to the open eye,then r the tube is taped to the skin of the orbital margins and filled with riboflavin 0.1%. The current intensity is initially 0.2 mA and then gradually increased to 1.0 mA at 0.2 mA for 1 minute at 10-second intervals increments to determine individual tolerance. The total time that the riboflavin administration is 10 minutes.

Standard surface UVA irradiation (370 nm, 3 mW/cm2) using UFalink device, (Russian Federation) is then applied at a 5-cm distance for 30 minutes with continuing hypotonic riboflavin drops every 2 minutes

Group Type EXPERIMENTAL

iontophoresis of riboflavin

Intervention Type PROCEDURE

Corneal collagen crosslinking

Intervention Type PROCEDURE

Standard surface UVA irradiation (370 nm, 3 mW/cm2; UFalink, Russian Federation) was then applied at a 5-cm distance for 30 minutes. During UVA exposure, hypotonic riboflavin drops were continued every 2 minutes.

galvanizator, Potok-1

Intervention Type DEVICE

Device for providing iontophoresis procedure

Riboflavin 0,1%

Intervention Type DRUG

UFalink

Intervention Type DEVICE

device for UVA irradiation - providing UVA light - 370 nm, 3 mW/cm2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

iontophoresis of riboflavin

Intervention Type PROCEDURE

epithelium-off

Intervention Type PROCEDURE

Corneal collagen crosslinking

Standard surface UVA irradiation (370 nm, 3 mW/cm2; UFalink, Russian Federation) was then applied at a 5-cm distance for 30 minutes. During UVA exposure, hypotonic riboflavin drops were continued every 2 minutes.

Intervention Type PROCEDURE

galvanizator, Potok-1

Device for providing iontophoresis procedure

Intervention Type DEVICE

Dextralink

Riboflavin 0,1% + Dextran T-500

Intervention Type DRUG

Riboflavin 0,1%

Intervention Type DRUG

UFalink

device for UVA irradiation - providing UVA light - 370 nm, 3 mW/cm2

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documented progressive KC (by Pentacam and/or corneal topography imaging).
* A clear central cornea.
* A minimal corneal thickness of ≥ 400 µm at the thinnest corneal location (Pentacam imaging).
* Minimal Snellen corrected distance visual acuity of ≥ 0.4.
* Patient age of ≥ 18 years.

Exclusion Criteria

* Corneal scarring.
* History of epithelial healing problems.
* History or presence of ocular infection (such as herpes keratitis)
* Pregnancy and/or breastfeeding.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ufa Eye Research Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mukharram Bikbov, Professor

Role: STUDY_CHAIR

Ufa Eye Research Institute

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TCXL-ionto

Identifier Type: -

Identifier Source: org_study_id